Infantile Myofibromatosis

• Infantile Myofibromatosis is a rare, benign tumor condition predominantly found in infants and young children.
• It is characterized by the development of single or multiple firm nodules in various body parts, including skin, muscle, bone, and internal organs.
• While often sporadic, some cases have a genetic basis, linked to mutations in genes like PDGFRB or NOTCH3.
• Symptoms vary depending on the location and number of tumors, ranging from visible skin lesions to more serious organ dysfunction.
• Treatment approaches range from watchful waiting for spontaneously regressing lesions to surgical removal or, in rare severe cases, chemotherapy.

What is Infantile Myofibromatosis and Its Causes?

Infantile Myofibromatosis is the most common fibrous tumor of infancy, though it remains a rare condition overall. It involves the proliferation of myofibroblasts, which are cells that play a crucial role in wound healing and tissue repair. These cells form distinct nodules or tumors that can occur in almost any part of the body. The condition can manifest as a solitary lesion (solitary infantile myofibromatosis) or multiple lesions (multicentric infantile myofibromatosis), which may involve skin, muscle, bone, and visceral organs.

The exact causes of infantile myofibromatosis are not fully understood, but it is believed to arise from an abnormal proliferation of myofibroblasts. Most cases are sporadic, meaning they occur without a clear genetic predisposition. However, a small percentage of cases are familial, indicating a genetic component. Research has identified mutations in genes such as PDGFRB (Platelet-Derived Growth Factor Receptor Beta) and NOTCH3 in some individuals with familial infantile myofibromatosis, suggesting these genetic alterations can contribute to the development of the condition. These mutations can lead to uncontrolled growth of myofibroblasts, forming the characteristic tumors.

Recognizing Infantile Myofibromatosis Symptoms

The presentation of infantile myofibromatosis symptoms can vary widely depending on the number, size, and location of the tumors. In many cases, the first sign is a firm, non-tender nodule that can be felt or seen under the skin. These lesions are typically flesh-colored or reddish-purple and do not usually cause pain unless they are pressing on nerves or growing rapidly. While skin and subcutaneous tissues are common sites, tumors can also affect deeper structures.

When tumors involve internal organs, the symptoms can be more severe and diverse. For instance, lesions in the gastrointestinal tract might lead to feeding difficulties, vomiting, or gastrointestinal bleeding. Tumors in the lungs could cause respiratory distress, while bone lesions might present as swelling or pain. The presence of multiple lesions, especially those affecting visceral organs, tends to be associated with a more complex clinical course. Early recognition of these symptoms is crucial for accurate diagnosis and appropriate management.

Common locations for these nodules include:

• Skin and subcutaneous tissue (most frequent)
• Skeletal muscle
• Bone
• Visceral organs (e.g., lungs, gastrointestinal tract, liver, pancreas)

Managing Infantile Myofibromatosis: Treatment Approaches

The approach to infantile myofibromatosis treatment is highly individualized and depends on several factors, including the number and location of the tumors, their size, and whether they are causing symptoms or affecting organ function. Given that many solitary lesions and some multicentric lesions have a propensity for spontaneous regression, a “watch and wait” approach is often adopted, especially for asymptomatic tumors that are not compromising vital functions.

For symptomatic lesions, those causing functional impairment, or those that are rapidly growing, more active intervention may be necessary. Surgical excision is the primary treatment for accessible tumors, aiming for complete removal while preserving surrounding healthy tissue. In cases where tumors are numerous, widespread, or involve critical organs and cannot be surgically removed, systemic therapies such as chemotherapy may be considered. These therapies are typically reserved for severe cases, particularly those with visceral involvement that poses a threat to life. The prognosis for infantile myofibromatosis is generally good, especially for solitary lesions, with most infants experiencing complete resolution or successful management.